This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stone, J. H Search for Related Content PubMed PubMed Citation Articles by Stone, J. H Social Bookmarking                   What's this?

End-stage renal disease in lupus: Disease activity, dialysis, and the outcome of transplantation

Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA

Lupus nephritis remains a major cause of morbidity in SLE. Approximately 10% of patients with SLE develop end-stage renal disease (ESRD). In most SLE patients, disease activity diminishes as ESRD approaches. Consequently, the survival of SLE patients on dialysis (both hemo-and peritoneal) appears to be comparable to that of non-SLE patients. However, the role of anti-phospholipid (aPL) antibodies in causing dialysis-related morbidity among patients with SLE requires further investigation. In contrast to the outcomes of dialysis, recent evidence suggests that renal transplantation outcomes among SLE patients are inferior to those of non-SLE patients, primarily because of the risk of recurrent lupus nephritis in the allograft and the effect of aPL-related events on transplantation outcomes. Future avenues of investigation should be directed at developing better strategies to manage and prevent these complications.

Key Words: dialysis • end-stage renal disease • lupus • transplantation

Lupus, Vol. 7, No. 9, 654-659 (1998)
DOI: 10.1191/096120398678920811


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. Rietveld and J. H. M. Berden Renal replacement therapy in lupus nephritis Nephrol. Dial. Transplant., October 1, 2008; 23(10): 3056 - 3060. [Full Text] [PDF]

				T. Yu, Y. Chen, J. Lan, C. Cheng, C. Chen, M. Wu, and K. Shu Renal outcome and evolution of disease activity in Chinese lupus patients after renal transplantation Lupus, July 1, 2008; 17(7): 687 - 694. [Abstract] [PDF]

				M Thomas, J Blennerhassett, and R Walker Relapse with transformation of lupus nephritis in a transplant kidney Lupus, July 1, 2005; 14(7): 554 - 556. [Abstract] [PDF]

				K Manger, B Manger, R Repp, M Geisselbrecht, A Geiger, A Pfahlberg, T Harrer, and J R Kalden Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus Ann Rheum Dis, December 1, 2002; 61(12): 1065 - 1070. [Abstract] [Full Text] [PDF]

				S L Lui, M F Lam, K C Tse, and W K Lo Reactivation of systemic lupus erythematosus in a dialysis patient after tuberculous peritonitis Lupus, January 1, 2002; 11(1): 49 - 51. [Abstract] [PDF]